BioDuro exits California as Forma Life Sciences takes over Irvine production sites

USA—Forma Life Sciences has officially entered the contract development and manufacturing organization (CDMO) market after acquiring BioDuro’s California production facilities earlier this year.

The company now operates as a dedicated CDMO specializing in oral solid-dosage pharmaceutical manufacturing.

BioSelective Capital Investments established the new organization in January when it purchased two BioDuro production and development facilities located in Irvine, California.

This strategic acquisition positioned Forma as a significant domestic manufacturing option for pharmaceutical and biotechnology companies seeking reliable U.S.-based production partners.

Extensive manufacturing capabilities

The acquisition delivered more than 100,000 square feet of manufacturing space to Forma’s portfolio.

The facilities house 27 specialized production suites capable of manufacturing over 2 billion tablets and capsules annually, providing substantial capacity for both clinical and commercial-scale operations.

Forma operates comprehensive services across both Irvine locations.

The company handles oral solid dose formulation development and supports clinical manufacturing throughout all three trial phases.

Additionally, the facilities accommodate process-scale-up activities, technology-transfer services, and full-scale commercial drug-product manufacturing.

Leadership with industry experience

Cyrus Mirsaidi serves as executive chairman and CEO of Forma.

He previously served as CEO of BioDuro from 2015 to 2021, bringing extensive experience in pharmaceutical manufacturing to his current role.

Armand Amin, another former BioDuro executive, joined Forma as president and head of business operations.

Amin emphasized the timing of Forma’s launch in relation to current industry trends.

“Our industry is seeing renewed focus on domestic pharmaceutical manufacturing and supply chain resilience,” he explained.

“Forma provides a durable, U.S.-based development and manufacturing platform that pharmaceutical and biotechnology partners can rely on from clinical development through commercial supply.”

Growing CDMO Sector

Forma joins several other CDMOs that have recently entered the market.

In early December, Quvara Medical launched operations after Buckland Group backed its purchase of a former Becton Dickinson manufacturing site in the United Kingdom.

The company did not disclose the acquisition price.

The CDMO sector witnessed additional notable launches throughout 2025.

New entrants included Rezon Bio, Codis, Meribel, and Artis BioSolutions, reflecting growing demand for contract manufacturing services across the pharmaceutical industry.

BioDuro’s strategic shift

BioDuro divested its Irvine facilities as part of a broader strategy to concentrate on its established manufacturing operations in Asia, particularly in China.

Earlier this week, the company announced a production joint venture with Cenra API Solutions, a Taiwanese active pharmaceutical ingredient manufacturer.

This partnership reinforces BioDuro’s commitment to strengthening its Asian manufacturing presence while exiting its California operations.